Amgen on Saturday said its cholesterol-lowering drug Repatha cut cardiovascular events by 25% when added on top of standard therapy in high-risk patients who have

Welcome back to another edition of Endpoints Weekly! Fall is in full swing here in New York, with chilly temperatures and multicolored trees settling in.

CMS plans to launch a new drug payment model for state Medicaid programs, the first of potentially multiple pricing models under President Donald Trump’s “most

The FDA told Biohaven its study using real-world data “would likely be inadequate to provide substantial evidence of effectiveness” when it was proposed, according to

Gilead’s Trodelvy failed to meet the primary endpoint in a Phase 3 trial for certain breast cancer patients, marking another setback for a key drug